Clinical Trials (PDQ®) - National Cancer Institute

Page Options

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights

Phase II Chemotherapy with Ftorafur for Metastatic Adenocarcinoma of the Colon and Rectum

Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outline
Published Results
Trial Contact Information

Basic Trial Information

Phase
Type
Status
Age
Sponsor
Protocol IDs

Phase II

Treatment

Completed

no age specified

NCI

SWOG-7619

Objectives

I.  Determine the efficacy of ftorafur in disseminated adenocarcinoma of the 
colon and rectum.

Entry Criteria

Disease Characteristics:

See General Eligibility Criteria

Patient Characteristics:

See General Eligibility Criteria

General Eligibility Criteria:

Patients with biopsy-proven 
adenocarcinoma of the colon or rectum with measurable recurrent or 
disseminated disease, with a life expectancy of at least 8 weeks.

Expected Enrollment

Protocol closed 09/77.  Protocol terminated 02/78.

Outline

Nonrandomized study.  Separately enter patients with and patients without 
liver metastases.
Arm I:  Single-agent Chemotherapy.  Ftorafur, NSC-148958.

Published Results

Buroker T, Padilla F, Groppe C, et al.: Phase II evaluation of ftorafur in previously untreated colorectal cancer: a Southwest Oncology Group study. Cancer 44(1): 48-51, 1979.

Trial Contact Information

Trial Lead Organizations

Southwest Oncology Group

Charles Coltman, MD, Protocol chair(Contact information may not be current)
Ph: 210-567-2710

Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol.